AI Summary
LLY and NVO dominate the U.S. weight-loss drug market. Morningstar predicts a $200 billion market by 2031 for weight-loss drugs. Goldman Sachs lowered its market estimate to $95 billion by 2030. Several competitors are emerging in the weight-loss drug sector. Amgen's MariTide shows promise but faces dropouts due to side effects.
Sentiment Rationale
LLY maintains a strong position in a growing market dominated by them and Novo. Historical stability in leading drug sectors suggests price resilience.
Trading Thesis
Market growth expectations are based on long-term trends, emergent competitors could influence in the coming years.
Market-Moving
- LLY and NVO dominate the U.S. weight-loss drug market.
- Morningstar predicts a $200 billion market by 2031 for weight-loss drugs.
- Goldman Sachs lowered its market estimate to $95 billion by 2030.
Key Facts
- LLY and NVO dominate the U.S. weight-loss drug market.
- Morningstar predicts a $200 billion market by 2031 for weight-loss drugs.
- Goldman Sachs lowered its market estimate to $95 billion by 2030.
- Several competitors are emerging in the weight-loss drug sector.
- Amgen's MariTide shows promise but faces dropouts due to side effects.
Companies Mentioned
- NVO (NVO)
- AMGN (AMGN)
- VKTX (VKTX)
- ZEAL (ZEAL)
- AZN (AZN)
Industry News
The competitive landscape in weight-loss drugs affects LLY's market positioning and future revenues.